Philip M. Hanno, MD, MPH
Philip M. Hanno, a Urology Times editorial consultant, is professor of urology at the University of Pennsylvania, Philadelphia.
http://www.urologytimes.com
Enigmatic disorder begins to yield to research

This issue of Urology Times includes a number of articles from one of the most successful meetings on interstitial cystitis ever held, the National Institute of Diabetes, Digestive, and Kidney Disorders and Interstitial Cystitis Association joint symposium "Research Insights into Interstitial Cystitis" in Alexandria, VA, last fall.

How drug therapy is changing the face of urology practice
Urology has always been a fascinating and somewhat hybrid specialty in the field of medicine. First and foremost, it has been a surgical specialty, requiring many years of intense surgical training to master. Many of us have been drawn to urology because of the wide assortment of surgical procedures and the ability to put to use the highest technological advancements in the course of our work.
Materials, techniques for SUI continue to evolve

New minimally invasive techniques for the surgical treatment of stress incontinence have been based on novel concepts concerning the surgical support of the mid-urethra and the utilization of artificial graft materials. In this exclusive Urology Times interview, David Staskin, MD, discusses the evolution of sling techniques and the pros and cons of using artificial materials. Dr. Staskin is director of the Section of Voiding Dysfunction, New York Presbyterian Hospital, and associate professor of urology and obstetrics and gynecology, Weill Medical College, Cornell University. The interview was conducted by UT Editorial Consultant Philip M. Hanno, MD, of the department of urology, University of Pennsylvania, Philadelphia.

On changing lanes: A few words of caution
In this issue of Urology Times, we see interviews with several urologists who have chosen to change paths in mid-career (see article, page 1). Having gone through many of these issues myself, a few words of caution are in order. Everyone goes through a period when they at least consider major changes, either because they have "been there, done that" and want something new, or perhaps changes are forced upon them for personal or health reasons. Most of us have gone through the medical tract in life on somewhat of a straightaway. We go from high school to college, from college to medical school, from medical school to surgical and urology training, and embark on our career. After several years of practice, looking at other fields and endeavors may be a natural progression for many of us.
IC research has answered many questions, but not all

This is an exciting time to be involved with interstitial cystitis, from the clinical aspect of caring for patients, to the search for markers and better methods of diagnosis, to the basic research so critical in ultimately finding etiologies and a cure. The articles in this month's Urology Times help to underscore these issues (see page 8). Tomohiro Ueda, MD, PhD, and colleagues have identified a cytokine inhibitor that seems to improve interstitial cystitis symptoms and increase bladder capacity, according to a preliminary trial in patients with non-ulcerative disease. The potassium chloride test study of Tony Yen-Huang Chen, MD, would appear to limit the usefulness of this potentially painful examination as a diagnostic adjunct. The profile that Frederic Liandier, MD, did of 287 IC patients serves to confirm that while we have many therapies for this disorder, nothing works for everyone and the treatment of IC is as much art as it is science-perhaps more so.

Poll

View Results